Beximco Launches First Remdesivir Generic
World’s First Generic Version Of COVID-19 Treatment Introduced In Bangladesh
Bangladesh's Beximco has claimed a world first with the launch of a generic version of remdesivir in its domestic market. Local authorities have granted an emergency use authorization for the COVID-19 treatment amid the coronavirus pandemic.
You may also be interested in...
While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic eﬀectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.
Pakistan’s Searle says it has struck a licensing and marketing deal with Bangladesh’s Beximco to market its generic remdesivir in Pakistan as the country grapples with the coronavirus pandemic.
Hetero is one of the new licensees for Gilead’s remdesivir, the investigational antiviral in the spotlight as a potential treatment for COVID-19, and the Indian group’s managing director shares insights on its supply chain readiness and the royalty model of the deal.